title: Is elevation of the serum β-d-glucan level a paradoxical sign for trichosporon fungemia in patients with hematologic disorders?
abstract: The detection of serum 1,3-β-d-glucan (BDG) has been reported to be useful for the diagnosis and therapeutic monitoring of various invasive fungal infections. Although Trichosporon fungemia is increasingly recognized as a fatal mycosis in immunocompromised patients, the utility of this assay for Trichosporon fungemia is still unknown. In our experience (28 cases), the level of BDG rose in about half of the patients with hematologic disorders who developed Trichosporon fungemia. Among them, early death from this infection was more frequently seen in BDG-negative patients than in BDG-positive patients. In addition, overall survival was also significantly worse in BDG-negative patients than in BDG-positive patients. There were no significant differences between these two patient groups in terms of clinical background. Unlike for other invasive fungal infections, elevation of BDG level may indicate a paradoxical sign for Trichosporon fungemia in patients with hematologic disorders.
authors.affiliation: Cancer Center, Mie University Hospital, 2-174 Edobashi, Tsu, Mie 514-8507, Japan. k2nakase@clin.medic.mie-u.ac.jp
authors.forename: Kazunori
authors.initials: K
authors.lastname: Nakase
authors.forename: Kei
authors.initials: K
authors.lastname: Suzuki
authors.forename: Taiichi
authors.initials: T
authors.lastname: Kyo
authors.forename: Tadahiro
authors.initials: T
authors.lastname: Kohara
authors.forename: Yumiko
authors.initials: Y
authors.lastname: Sugawara
authors.forename: Naoyuki
authors.initials: N
authors.lastname: Katayama
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D054714:Echinocandins / Q000627:therapeutic use; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use; D016469:Fungemia / Q000175:diagnosis* / Q000188:drug therapy / Q000382:microbiology; D006402:Hematologic Diseases / Q000175:diagnosis* / Q000188:drug therapy; D006801:Humans; D016867:Immunocompromised Host; D055666:Lipopeptides / Q000627:therapeutic use; D008297:Male; D000077551:Micafungin; D008825:Miconazole / Q000627:therapeutic use; D008875:Middle Aged; D011509:Proteoglycans; D012189:Retrospective Studies; D016896:Treatment Outcome; D014250:Trichosporon / Q000187:drug effects / Q000472:pathogenicity*; D055815:Young Adult; D047071:beta-Glucans / Q000097:blood*
chemical_list: D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D011509:Proteoglycans; D047071:beta-Glucans; C010770:polysaccharide-K; D008825:Miconazole; D000666:Amphotericin B; D015725:Fluconazole; D000077551:Micafungin